Central Venous Catheter - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The central venous catheter market size is expected to grow from USD 2.53 billion in 2025 to USD 2.69 billion in 2026 and is forecast to reach USD 3.67 billion by 2031 at 6.40% CAGR over 2026-2031. This report is Segmented by Product Type (Non-Tunneled, Tunneled CVCs, Piccs, Implanted Ports), Lumen (Single, Double, Triple, Multi-Lumen), Material (Polyurethane, Silicone, Others), Application (Drug Admin., Fluid/Nutrition, Blood Transfusion, Diagnostics), End User (Hospitals, Ascs, Clinics, Home Healthcare), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in USD Value.

Global Central Venous Catheter Market Trends and Insights

Rising Cancer, Dialysis, and Critical-Care Demand

The central venous catheter market continues to gain from cancer, dialysis, and critical care cases that require repeated access, reliable infusion, and controlled administration over extended treatment periods. Dialysis remains a key demand driver, as healthcare providers use tunneled catheters as bridging access when fistulas are not ready. Critical care also supports market growth, as patients in intensive care settings often need vasoactive drugs, blood products, monitoring, and nutritional support through a single access route. The overlap between oncology and kidney disease increases catheter use per patient when individuals require both chemotherapy and dialysis support. Public program expansion in countries such as India shows how higher service capacity can increase catheter placements in real care settings.

Increasing Preference for Power-Injectable Central Venous Catheters

Hospitals are increasingly adopting power-injectable systems as contrast-enhanced imaging becomes routine in cancer diagnosis, staging, and follow-up care. When catheters cannot support high-pressure contrast injection, clinicians often need an additional access step, which increases workload and patient inconvenience. Protocol-driven hospitals now treat power-injectable peripherally inserted central catheters (PICCs) and ports as standard specifications rather than optional premium upgrades. This shift benefits suppliers that combine catheter performance, insertion safety, and simplified workflow design in a single platform. BD’s CentroVena One launch reflects this direction, with a focus on integrated insertion, fewer procedural steps, and use in high-acuity environments.

Catheter-Related Bloodstream Infection Risk

Infection risk continues to affect confidence in central access, despite stronger prevention protocols. The WHO’s 2024 guidance states that bloodstream infections associated with intravascular catheters require strict procedural discipline and continuous oversight. Hospitals also face reporting pressure, reimbursement consequences, and internal reviews when central line-associated bloodstream infection (CLABSI) events occur, extending the burden beyond clinical harm. Thrombosis adds further concern, as it can interrupt therapy, require catheter removal, and increase treatment costs for already fragile patients. A 2026 retrospective cohort study in BMC Surgery confirmed that tunneled non-cuffed centrally inserted catheters in oncology patients still carry meaningful thrombosis risk despite optimized placement protocols. This restraint remains important for the central venous catheter market because safety concerns can slow adoption when buyers compare central access with less invasive options in selected cases.

Other drivers and restraints analyzed in the detailed report include:

• Infection-Prevention Bundling and Chlorhexidine Adoption
• Longer Dwell-Time Use in Home Infusion and Ambulatory Settings
• Pricing Pressure from Value-Based Procurement and Tenders

Segment Analysis

Peripherally inserted central catheters (PICCs) are expected to account for 38.12% of the product type segment in 2025, maintaining the leading position across intermediate-duration therapies. Their use remains strong in antibiotic infusion, chemotherapy cycles, and treatments that require reliable access without immediate surgical implantation. Non-tunneled catheters support acute hospital needs, while tunneled devices remain important in dialysis and chronic oncology care. This mix keeps the central venous catheter market balanced between high-volume acute use and durable long-term access.

Implanted ports are projected to be the fastest-growing product category, registering a 9.53% compound annual growth rate (CAGR) from 2026 to 2031, driven by stronger demand in oncology and pediatric care. Their fully subcutaneous design improves patient comfort, lowers visibility, and supports extended treatment needs. Hybrid concepts, such as PICC-PORT designs, indicate a shift toward flexible access options for difficult anatomies. This category is gaining importance as suppliers pursue differentiation in high-value and long-dwell applications.

Double lumen catheters are expected to hold a 42.45% share in 2025, making them the leading lumen type across dialysis and multi-drug hospital protocols. Dialysis requires simultaneous withdrawal and return, while oncology and intensive care regimens benefit from separated channels. Single lumen devices support simpler therapies, and triple lumen configurations remain relevant in high-acuity care. Lumen selection in the central venous catheter market remains closely linked to treatment complexity.

Multi-lumen catheters are projected to be the fastest-growing lumen category, registering an 8.67% CAGR through 2031, as care pathways require more simultaneous infusions through fewer insertion sites. Fewer insertion points can reduce patient access burden and simplify complex hospital protocols. Innovation is also advancing lumen-level performance, including surfaces designed to reduce clot formation and support longer use. Suppliers that improve channel functionality without complicating insertion are likely to stay well positioned.

Complete Report Scope:

• By Product Type
  • Non-Tunneled Central Venous Catheters
  • Tunneled Central Venous Catheters
  • Peripherally Inserted Central Catheters
  • Implanted Ports
• By Lumen Type
  • Single Lumen
  • Double Lumen
  • Triple Lumen
  • Multi-Lumen
• By Material
  • Polyurethane
  • Silicone
  • Other Materials
• By Application
  • Drug Administration
  • Fluid and Nutrition Administration
  • Blood Transfusion
  • Diagnostics and Testing
• By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Specialty Clinics
  • Home Healthcare Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America is expected to hold a 41.56% share in 2025, maintaining its position as the largest regional block in the central venous catheter market. Strong infection-control standards, established hospital accreditation requirements, and broad adoption of premium antimicrobial and power-injectable device types support the region’s leadership. The United States remains especially important, as clinical protocols, mature contracting channels, and strong demand for workflow-improving technologies support premium device adoption. Canada and Mexico contribute steady growth, while product differentiation is shifting toward insertion systems, securement, and integrated workflow design rather than basic catheter access alone.

Europe remains the second-largest geographic block in the central venous catheter market, supported by large oncology treatment programs and established dialysis networks in Germany, France, and the United Kingdom. Italy and Spain add incremental demand through aging demographics and expanding outpatient infusion capabilities. Regulatory expectations under the European Union Medical Device Regulation increase the burden for newer entrants, especially in coated and antimicrobial categories where sustained post-market clinical follow-up remains important. B. Braun’s 2025 results, expected to be published in 2026, are expected to show EUR 584 million in research and development spending, with an 11% year-on-year increase, underlining continued investment in connected infusion and vascular access capabilities.

Asia-Pacific is the fastest-growing region in the central venous catheter market, with a projected compound annual growth rate of 10.56% from 2026 to 2031. Hospital capacity expansion, a rising chronic disease burden, and stronger public investment in dialysis and cancer care infrastructure drive regional growth. India benefits from dialysis program expansion, which supports tunneled catheter placement where fistula-based access is not yet available. China is developing along two tracks, with multinational suppliers competing on premium performance in top-tier hospitals while domestic manufacturers remain active in cost-sensitive procurement channels.

List of Companies Covered in this Report:

• AngioDynamics
• Argon Medical Devices
• B. Braun
• Beckton Dickinson
• Cardinal Health
• Cook Group
• Delta Med S.p.A.
• Edward Lifesciences
• Fresenius Medical Care AG and Co. KGaA
• Halyard Health, Inc.
• ICU Medical
• Lepu Medical Technology (Beijing) Co., Ltd.
• Medtronic
• Merit Medical Systems
• Nipro
• Poly Medicure
• Smiths Group
• Teleflex
• Terumo
• Vygon

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support